Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M. Ebbo is active.

Publication


Featured researches published by M. Ebbo.


Medicine | 2012

Igg4-related Systemic Disease: Features and Treatment Response in a French Cohort

M. Ebbo; Laurent Daniel; M. Pavic; P. Sève; M. Hamidou; Emmanuel Andres; S. Burtey; L. Chiche; Jacques Serratrice; Maïté Longy-Boursier; M. Ruivard; Julien Haroche; Bertrand Godeau; Anne-Bérengère Beucher; Jean-Marie Berthelot; Thomas Papo; Jean-Loup Pennaforte; A. Benyamine; Noémie Jourde; Cédric Landron; P. Roblot; Olivier Moranne; Christine Silvain; Brigitte Granel; Fanny Bernard; V. Veit; K. Mazodier; E. Bernit; Hugues Rousset; José Boucraut

AbstractIgG4-related systemic disease is now recognized as a systemic disease that may affect various organs. The diagnosis is usually made in patients who present with elevated IgG4 in serum and tissue infiltration of diseased organs by numerous IgG4+ plasma cells, in the absence of validated diagnosis criteria. We report the clinical, laboratory, and histologic characteristics of 25 patients from a French nationwide cohort. We also report the treatment outcome and show that despite the efficacy of corticosteroids, a second-line treatment is frequently necessary. The clinical findings in our patients are not different from the results of previous reports from Eastern countries. Our laboratory and histologic findings, however, suggest, at least in some patients, a more broad polyclonal B cell activation than the skewed IgG4 switch previously reported. These observations strongly suggest the implication of a T-cell dependent B-cell polyclonal activation in IgG4-related systemic disease, probably at least in part under the control of T helper follicular cells.


Nature Immunology | 2016

Evidence of innate lymphoid cell redundancy in humans

Frédéric Vély; Vincent Barlogis; Blandine Vallentin; Bénédicte Neven; Christelle Piperoglou; M. Ebbo; Thibaut Perchet; Maxime Petit; Nadia Yessaad; Fabien Touzot; Julie Bruneau; Nizar Mahlaoui; Nicolas Zucchini; Catherine Farnarier; Gérard Michel; Despina Moshous; Stéphane Blanche; Arnaud Dujardin; Hergen Spits; Jörg H W Distler; Andreas Ramming; Capucine Picard; Rachel Golub; Alain Fischer; Eric Vivier

Innate lymphoid cells (ILCs) have potent immunological functions in experimental conditions in mice, but their contributions to immunity in natural conditions in humans have remained unclear. We investigated the presence of ILCs in a cohort of patients with severe combined immunodeficiency (SCID). All ILC subsets were absent in patients with SCID who had mutation of the gene encoding the common γ-chain cytokine receptor subunit IL-2Rγ or the gene encoding the tyrosine kinase JAK3. T cell reconstitution was observed in patients with SCID after hematopoietic stem cell transplantation (HSCT), but the patients still had considerably fewer ILCs in the absence of myeloablation than did healthy control subjects, with the exception of rare cases of reconstitution of the ILC1 subset of ILCs. Notably, the ILC deficiencies observed were not associated with any particular susceptibility to disease, with follow-up extending from 7 years to 39 years after HSCT. We thus report here selective ILC deficiency in humans and show that ILCs might be dispensable in natural conditions, if T cells are present and B cell function is preserved.


Arthritis Care and Research | 2014

Usefulness of 2‐[18F]‐fluoro‐2‐deoxy‐d‐glucose–Positron Emission Tomography/Computed Tomography for Staging and Evaluation of Treatment Response in IgG4‐Related Disease: A Retrospective Multicenter Study

M. Ebbo; A. Grados; Eric Guedj; Delphine Gobert; Cécile Colavolpe; Mohamad Zaidan; Agathe Masseau; Fanny Bernard; Jean-Marie Berthelot; Nathalie Morel; François Lifermann; S. Palat; Julien Haroche; Xavier Mariette; Bertrand Godeau; E. Bernit; Nathalie Costedoat-Chalumeau; Thomas Papo; Mohamed Hamidou; J.-R. Harle; N. Schleinitz

To evaluate the usefulness of 2‐[18F]‐fluoro‐2‐deoxy‐d‐glucose–positron emission tomography/computed tomography (FDG‐PET/CT) in IgG4‐related disease (IgG4‐RD) for the staging of the disease and the followup under treatment.


Journal of Clinical Investigation | 2013

B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells

Matthieu Mahévas; Pauline Patin; François Huetz; Marc Descatoire; Nicolas Cagnard; Christine Bole-Feysot; Simon Le Gallou; Mehdi Khellaf; Olivier Fain; David Boutboul; Lionel Galicier; M. Ebbo; Olivier Lambotte; M. Hamidou; Philippe Bierling; Bertrand Godeau; Marc Michel; Jean-Claude Weill; Claude-Agnès Reynaud

Primary immune thrombocytopenia (ITP) is a disorder caused by autoantibody-mediated platelet destruction and decreased platelet production. Rituximab, a B cell-depleting agent, has become the first-line treatment for ITP; however, patients with refractory disease usually require splenectomy. We identified antibody-secreting cells as the major splenic B cell population that is resistant to rituximab. The phenotype, antibody specificity, and gene expression profile of these cells were characterized and compared to those of antibody-secreting cells from untreated ITP spleens and from healthy tissues. Antiplatelet-specific plasma cells (PC) were detected in the spleens of patients with ITP up to 6 months after rituximab treatment, and the PC population displayed a long-lived program similar to the one of bone marrow PC, thus explaining for most of these patients the absence of response to rituximab and the response to splenectomy. When analyzed by multiplex PCR at the single-cell level, normal splenic PC showed a markedly different gene expression profile, with an intermediate signature, including genes characteristic of both long-lived PC and proliferating plasmablasts. Surprisingly, long-lived PC were not detected in untreated ITP spleens. These results suggest that the milieu generated by B cell depletion promotes the differentiation and settlement of long-lived PC in the spleen.


International Journal of Rheumatology | 2012

Pathologies Associated with Serum IgG4 Elevation

M. Ebbo; A. Grados; E. Bernit; Frédéric Vély; José Boucraut; Jean-Robert Harlé; Laurent Daniel; Nicolas Schleinitz

Statement of Purpose. IgG4-related disease (IgG4-RD) is usually associated to an increase of serum IgG4 levels. However other conditions have also been associated to high serum IgG4 levels. Methods. All IgG subclasses analyses performed in our hospital over a one-year period were analyzed. When IgG4 level were over 1.35 g/L, the patients clinical observation was analyzed and both final diagnosis and reason leading to IgG subclasses analysis were recorded. Only polyclonal increases of IgG4 were considered. Summary of the Results. On 646 IgG subclass analysis performed, 59 patients had serum IgG4 over 1.35 g/L. The final diagnosis associated to serum IgG4 increase was very variable. Most patients (25%) presented with repeated infections, 13.5% with autoimmune diseases, and 10% with IgG4-RD. Other patients presented with cancer, primary immune deficiencies, idiopathic interstitial lung disease, cystic fibrosis, histiocytosis, or systemic vasculitis and 13.5% presented with various pathologies or no diagnosis. Mean IgG4 levels and IgG4/IgG ratio were higher in IgG4-RD than in other pathologies associated to elevated IgG4 levels. Conclusions. Our study confirms that elevation of serum IgG4 is not specific to IgG4-RD. Before retaining IgG4-RD diagnosis in cases of serum IgG4 above 1.35 g/L, several other pathological conditions should be excluded.


Blood | 2014

Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients

Mehdi Khellaf; Anaı̈s Charles-Nelson; Olivier Fain; Louis Terriou; Jean-François Viallard; Stéphane Cheze; J. Graveleau; Borhane Slama; S. Audia; M. Ebbo; Guillaume Le Guenno; Manuel Cliquennois; Gilles Salles; Caroline Bonmati; Lionel Galicier; Arnaud Hot; Olivier Lambotte; François Lefrère; Salimatou Sacko; Dieudonné Kilendo Kengue; Philippe Bierling; F. Roudot-Thoraval; Marc Michel; Bertrand Godeau

We conducted a prospective multicenter registry of 248 adult patients with immune thrombocytopenia (ITP) treated with rituximab to assess safety. We also assessed response and predictive factors of sustained response. In total, 173 patients received 4 infusions of 375 mg/m(2) and 72 received 2 fixed 1-g infusions 2 weeks apart. The choice of the rituximab regimen was based on the physicians preference and not patient characteristics. Overall, 38 patients showed minor intolerance to rituximab infusions; infusions had to be stopped for only 3 patients. Seven showed infection (n = 11 cases), with an incidence of 2.3 infections/100 patient-years. Three patients died of infection 12 to 14 months after rituximab infusions, but the role of rituximab was questionable. In total, 152 patients (61%) showed an overall initial response (platelet count ≥30 × 10(9)/L and ≥2 baseline value). At a median follow-up of 24 months, 96 patients (39%) showed a lasting response. On multivariate analysis, the probability of sustained response at 1 year was significantly associated with ITP duration <1 year (P = .02) and previous transient complete response to corticosteroids (P = .05). The pattern of response was similar with the 2 rituximab regimens. With its benefit/risk ratio, rituximab used off-label may remain a valid option for treating persistent or chronic ITP in adults. This trial was registered at www.clinicaltrials.gov as #NC1101295.


British Journal of Haematology | 2014

The temporary use of thrombopoietin‐receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study

Matthieu Mahévas; Olivier Fain; M. Ebbo; F. Roudot-Thoraval; Nicolas Limal; Mehdi Khellaf; N. Schleinitz; Philippe Bierling; Laeticia Languille; Bertrand Godeau; Marc Michel

Thrombopoietin‐receptor agonists (Tpo‐RAs) are highly effective in immune thrombocytopenia (ITP). Recently, cases of durable remission after Tpo‐RA discontinuation in adult ITP have been reported. We aimed to describe the subset of patients in whom transient Tpo‐RA therapy may induce a durable response. We studied all adults with primary ITP treated with at least one Tpo‐RA over a 5‐year period (n = 54) and seen at one of three participating referral centres in France. Tpo‐RAs were discontinued in 20 of 28 patients who achieved a complete response. We excluded six patients because a previous treatment at the start of Tpo‐RA treatment may have interfered with the response. Overall, eight patients with chronic ITP showed a sustained response [median follow‐up: 13·5 months (range 5–27 months)]. We could not identify a predictive factor of sustained response. In conclusion, a substantial proportion of ITP patients receiving Tpo‐RAs can maintain a durable response after treatment discontinuation.


Nature Reviews Immunology | 2017

Innate lymphoid cells: major players in inflammatory diseases

M. Ebbo; Adeline Crinier; Frédéric Vély; Eric Vivier

Recent years have seen a marked increase in our understanding of innate lymphoid cells (ILCs). ILCs can be classified into different groups based on their similarity to T cell subsets in terms of their expression of key transcription factors and cytokine production. Various immunological functions of ILCs have been described, and increasing numbers of studies have implicated these cells in inflammatory disorders. Here, we detail the roles of ILCs in inflammatory diseases; we cover type 2 inflammatory diseases (such as asthma, chronic rhinosinusitis and atopic dermatitis), as well as inflammatory bowel diseases, psoriasis and other systemic or organ-specific inflammatory and autoimmune diseases. Future directions in the field are discussed, together with potential avenues of treatment.


Arthritis & Rheumatism | 2015

The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fifty‐Seven Patients

Marie Jachiet; B. Flageul; Alban Deroux; Alain Le Quellec; F. Maurier; Florence Cordoliani; Pascal Godmer; C. Abasq; Leonardo Astudillo; P. Belenotti; D. Bessis; Adrien Bigot; M.-S. Doutre; M. Ebbo; Isabelle Guichard; E. Hachulla; Emmanuel Héron; Géraldine Jeudy; N. Jourde-Chiche; D. Jullien; C. Lavigne; L. Machet; Marie‐Alice Macher; Clotilde Martel; Sara Melboucy-Belkhir; Cécile Morice; Antoine Petit; Bernard Simorre; Thierry Zenone; Laurence Bouillet

Hypocomplementemic urticarial vasculitis (HUV) is an uncommon vasculitis of unknown etiology that is rarely described in the literature. We undertook this study to analyze the clinical spectrum and the therapeutic management of patients with HUV.


Arthritis Care and Research | 2013

Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases.

Nina Droz; Laurent Gilardin; Patrice Cacoub; Francis Berenbaum; Daniel Wendling; Bertrand Godeau; A.-M. Piette; Emmanuelle Dernis; M. Ebbo; Bruno Fautrel; Guillaume Le Guenno; A. Mekinian; Brigitte Bernard-Chabert; Nathalie Costedoat-Chalumeau; Elodie Descloux; Jean-Marie Michot; Sylvie Radenne; Aude Rigolet; S. Rivière; Jean-Luc Yvin; Vincent Thibault; D. Thabut; Stanislas Pol; Loïc Guillevin; Luc Mouthon; Benjamin Terrier

Immunosuppressive therapy may trigger hepatitis B virus (HBV) reactivation for increased morbidity and mortality. We aimed to describe HBV reactivation in patients receiving treatment for immune‐mediated inflammatory diseases (IMIDs) and to evaluate a predefined algorithm for its prevention.

Collaboration


Dive into the M. Ebbo's collaboration.

Top Co-Authors

Avatar

N. Schleinitz

Aix-Marseille University

View shared research outputs
Top Co-Authors

Avatar

J.-R. Harle

Aix-Marseille University

View shared research outputs
Top Co-Authors

Avatar

E. Bernit

Aix-Marseille University

View shared research outputs
Top Co-Authors

Avatar

A. Grados

Aix-Marseille University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G. Kaplanski

Aix-Marseille University

View shared research outputs
Top Co-Authors

Avatar

J.-M. Durand

Aix-Marseille University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge